TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05459649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Oral Product
Description: A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
Study: NCT05955261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV over 30 minutes on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV over 30 minutes q12 hours on days 1-8 (16 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV over 30 minutes q12 hours on days 1-8 (16 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV over 30 minutes q12 hours on days 1-8 (16 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: IV over 1 hour on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: IV over 1 hour on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: IV over 1 hour on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV over 30 minutes on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV over 30 minutes on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: Given IV over 15 minutes on days 3-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: Given IV over 15 minutes on days 3-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin Hydrochloride
Description: Given IV over 15 minutes on days 3-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: IV over 1 hour on days 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: IV over 1 hour on days 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV over 1 hour on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV over 1 hour on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV over 1 hour on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: PO on days 8-28 (21 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: PO on days 8-28 (21 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: PO on days 8-28 (21 doses)
Study: NCT05760885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training with sensory augmentation
Description: Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
Study: NCT06057012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-296
Description: BRII-296 will be given via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo Medrol
Description: Depo Medrol will be given via intramuscular injection.
Study: NCT04258813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iGuide Intervention (Self-guided)
Description: The iGuide Intervention consists of two patient-level and four PCP-level components. These components include: (1) the patient-level brief video vignettes with a written summary; and (2) patient-facing webinars. The investigators will not use any institutional branding in the videos, printed materials, or recorded webinars so that these deliverables can be used in other settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iGuide 2 Intervention (Tailored/Targeted)
Description: The iGuide2 patient-level intervention will use a stage-based, tailored approach to four monthly 5-minute video vignettes that incorporates a pre-video worksheet. The investigators will send the worksheets and video vignettes in the method preferred by the patient.~The targeted iGuide 2 PCP-level intervention will include a cancer specialist-facing dashboard that includes the specialists's patients who are enrolled in the study and are in the intervention arm. The HEDIS quality measures for our three CVD comorbidities will be used. The dashboard will be populated with data available in Epic for the specific patient. If some information is missing (i.e., there is no lipid profile in the laboratory tab), the dashboard will query the PCP via an e-consult, asking to supply the information. Bimonthly, starting with the second randomization, an asynchronous specialist-to-PCP e-consult will be sent to PCPs whose patient(s) do not meet all three of the HEDIS quality metrics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants randomized to the control group (n=400) will receive current guideline-concordant cancer care. The investigators will also provide information for healthy living during and after cancer and for preparing for transition from cancer therapy to follow-up care. Monthly, patient education material on healthy living will be sent to the participants via the patient portal or by mail, based on participant preference. At the completion of therapy, they will be provided the NCI Facing Forward:Life After Cancer booklet. Note, this approach is not fully equivalent to an attention control as there will be touch points in the iGuide and iGuide2 interventions that the investigators cannot match for the control group. Also, the research team will not engage the PCPs in clinics randomized to the control group.
Study: NCT05726227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously once-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously once-weekly.
Study: NCT06532422

Intervention type: PROCEDURE
Intervention: Partial or total laparoscopic nephrectomy
Description: Nephrectomy is currently the primary indication for localised kidney cancer. All patients consulting a surgeon at the Clinique de la Sauvegarde for localised kidney cancer, for which surgical excision has been validated by the multidisciplinary consultation meeting and who are eligible for outpatient treatment, will be offered the opportunity to take part in this study during the preoperative consultation.
Study: NCT06570018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post operative enhanced recovery elements
Description: According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
Study: NCT06324721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography)
Description: Assessments related to different types of breast cancer related lymphedema at arm (1. self-reported swelling at arm, 2. subjective arm lymphedema, 3. objective arm lymphedema) using the Norman questionnaire, volume measurements (volumetry and perimetry), bioimpedance spectroscopy, and bioimpedance analysis~Assessments related to different types of breast cancer related lymphedema at trunk/ breast (1. self-reported swelling at trunk/ breast, 2. subjective trunk/ breast lymphedema, 3. objective trunk/ breast lymphedema) using the Norman questionnaire, tissue dielectric measurements, and ultrasonography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy)
Description: Clinical assessments related to lymphatic problems (1. amount of swelling at arm by relative arm volume difference, 2. amount of swelling at trunk by percentage water ratio, 3. severity of dermal rerouting at upper limb and trunk by lymphofluoroscopy (i.e., near-infrared fluorescence imaging device)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements for sensory processing problems by monofilaments, algometer, goniometer, and neurosensory analyzer
Description: Clinical measurements related to nociceptive, neuropathic and central sensory problems based on the Quantitative Sensory Testing principles using different devices algometer, goniometer, standardized set of monofilaments, and neurosensory analyzer
Study: NCT06389136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose A
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose A
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose A
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose A
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Dose A
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose B
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose B
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib Dose B
Description: Oral tablet
Study: NCT04943289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DUOC-01
Description: DUOC-01 is a population of cells expanded from donor human umbilical cord blood mononuclear cells. DUOC-01 cells are derived from CB CD14+ monocytes. DUOC-01 will be administered along with hydrocortisone via intrathecal injection.
Study: NCT06571045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for intravitreal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYE103
Description: EYE103 is a humanized antibody formulated for intravitreal administration
Study: NCT06236438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenously (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenously (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenously (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion
Study: NCT05425394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delay first bath
Description: Newborns delay first bath to 8 hours after birth
Study: NCT05484505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch, Nicotine gums
Description: Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, Nicotine gums
Description: Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice (5 A's & 5 R's)
Description: Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice (5 A's & 5 R's)
Description: Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch: Preloading for 4 weeks
Description: Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
Study: NCT05984654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma therapy
Description: Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma therapy
Description: Approximately 30 ml of the patient's blood sample will be drawn from a peripheral vein in ACD (acid citrate dextrose) tubes. A double spin method will be used for the preparation of PRP.~Note this is not a device or a medicine as this is autologous plasma.
Study: NCT06236438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion
Study: NCT05718167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab injection
Description: Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
Study: NCT05215808

Intervention type: DRUG
Group type: OTHER
Intervention: RBN-3143
Description: Oral Administration of tablets

Intervention type: DRUG
Group type: OTHER
Intervention: RBN-3143
Description: Oral Administration of tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBN-3143
Description: Oral Administration of tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBN-3143
Description: Oral Administration of tablets
Study: NCT06127381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic acid tetrasubstituted piceatannol (TGKP)
Description: A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic acid tetrasubstituted piceatannol (TGKP)
Description: A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycolic acid tetrasubstituted piceatannol (TGKP)
Description: A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
Study: NCT06236438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Injection
Study: NCT05456542

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cuff Leak Test
Description: Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
Study: NCT06236438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion
Study: NCT06570473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Tablet
Study: NCT06080178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-lyte (static group)
Description: Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg